Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
7,209 people get AMRN articles and Market Currents by email alert.
Get email alerts on AMRN »
FOCUS
|
PRO
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
To learn more about Seeking Alpha Pro, click here.
-
Amarin Management Discusses Q3 2012 Results - Earnings Call TranscriptThu, Nov 8, 2012 • 3 Comments
-
Amarin's CEO Discusses Q2 2012 Results - Earnings Call TranscriptWed, Aug 8, 2012 • 4 Comments
-
Amarin Corporation plc Q2 2008 Earnings Call TranscriptThu, Sep 25, 2008 • 1 Comment
-
GlobeNewswire (May 30, 2013)
-
GlobeNewswire (May 9, 2013)
-
GlobeNewswire (May 3, 2013)
-
at CNBC.com (Mar 21, 2013)
-
GlobeNewswire (Feb 28, 2013)
-
GlobeNewswire (Feb 22, 2013)
-
GlobeNewswire (Feb 21, 2013)
-
GlobeNewswire (Feb 7, 2013)
AMRN vs. ETF Alternatives
Company Description
Amarin Corporation plc is a late-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. Amarin has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the use of its lead product candidate, AMR101,... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Tuesday, June 18, 12:33 PM Amarin (AMRN -0.5%) continues its slide on the back of Friday's news that NCE status on Vascepa was once again delayed. However, MKM Partners analyst Jon LeCroy thinks the delay may have a silver lining. Lecroy says that while the NCE designation is the preferred outcome here, the delay also prevents the company from being targeted for a takeover. The shares are likely to remain under pressure until an NCE decision is made though, which MKM expects to come around July 12. 5 Comments [Healthcare]
-
Thursday, May 30, 9:13 AM
Premarket gainers: NVE +22%. CLWR +20%. MY +15%. CLSN +13%. HSOL +12%. CPST +10%. EXPR +9%. LXRX +8%. BLDP +8%. VRNG +7%. RSOL +6%. WFR +6%. AMRN +6%. FSLR +6%. ALU +6%. EMC +6%. STP +5%. HIMX +5%. OCZ +5%.
Losers: ABIO -31%. BIG -9%. VNR -5%. BPFH -5%. 1 Comment [On the Move] - Thursday, May 30, 8:26 AM Dr Eliot Brinton says research firm Summer Street misquoted him in its bearish report on Amarin (AMRN +5.3%) and denies that he said that the FDA won't authorize the company's prescription-grade fish oil Vascepa without further clinical data. Meanwhile, Amarin reports further positive results for Vascepa when taken in conjunction with statins. 4 Comments [Healthcare, On the Move]
- Wednesday, May 29, 9:58 AM AstraZeneca's (AZN -1.5%) $443M deal to acquire Omthera puts the U.K. company at "distinct commercial advantage" over Amarin (AMRN +0.3%), says Decision Resources' Paramjit Narang. Omthera's Epanova drug "offers higher and more constant bioavailability, and arguably better efficacy" in lowering triglyceride than Amarin's Vascepa, and it "lacks the gastrointestinal side effects of the market incumbent Lovaza," which is sold by GSK (GSK -2%). Narang reckons Epanova's annual sales could peak at $1B. 9 Comments [Healthcare, M&A]
- Tuesday, May 28, 12:40 PM Amarin (AMRN -6.4%) trades lower on negative comments out of Summer Street this morning, saying that Vascepa might not be as key as previously thought. The firm notes that a member of AMRN's steering committee presented at a primary care conference last week, and said there was no reason to give Vascepa to patients with triglycerides <500 mg/dL until the outcome of current trials are completed, and, even if approval is granted early, sales are likely to disappoint. 8 Comments [Healthcare, On the Move]
- Wednesday, May 22, 2:07 PM After an early 5% pop to the upside, Amarin (AMRN -0.9%) reverses course to trade lower after the company said the USPTO published a notification tied to its combination product of Vascepa and Statin Therapy. The application is part of AMRN's expansive portfolio, which includes 23 patent applications either issued or allowed, and over 30 applications pending in the U.S. 2 Comments [Healthcare, On the Move]
- Wednesday, May 22, 6:58 AM The U.S. Patent Office publishes a Notice of Allowance for Amarin's (AMRN) application "intended to protect the [combination of] Vascepa and statin therapy." (PR) 1 Comment [Healthcare]
- Friday, May 17, 3:43 PM Shares of Amarin (AMRN -1.1%) rebound somewhat from an earlier dip on news that its Vascepa wasn't in the FDA's Orange Book for April. 5 Comments [Healthcare, On the Move]
- Thursday, May 9, 5:43 PM Amarin (AMRN): Q1 EPS of -$0.41 misses by $0.02. (PR) 2 Comments [Earnings, Breaking News, Healthcare]
- Tuesday, April 23, 9:15 AM Amarin (AMRN) says the FDA has accepted its supplemental new drug application for Vascepa and set a December 20 target date to complete its regulatory review. The company's seeking approval of the the cholesterol-reducing fish-oil pill as an adjunct to diet for the treatment of high triglycerides with mixed dyslipidemia. Shares +6.2% in pre-market trading. 8 Comments [Healthcare, On the Move]
-
Tuesday, April 23, 9:10 AM
Premarket gainers: MEMS +50%. SCON +46%. NFLX +24%. VECO +14%. COH +12%. ILMN +10%. ARMH +9%. CZR +8%. STM +6%. AMRN +6%.
Losers: IRWD -10%. RSH -7%. IOC -6%. Comment! [On the Move] - Thursday, April 18, 8:53 AM Amarin (AMRN) rises 2.49% premarket after saying the FDA has approved its Supplemental New Drug Application to add Chemport as a supplier of ingredients for Vascepa, AMRN's first approved product. The move comes as AMRN attempts to expand its supply chain and protect Vascepa's commercial potential by "taking advantage of manufacturing barriers to entry." Comment! [Healthcare, On the Move]
- Friday, April 12, 12:03 PM Amarin (AMRN -2%) trades lower on reports that Vascepa's exclusivity status isn't in FDA Orange Book update for March. Earlier this week the drug was listed in a report by EvaluatePharma called "The industry's brightest hopes: where are they now?" as the fourth most disappointing drug, having seen lofty expectations of a potential $2B annual market dwindle down to just $505M. 5 Comments [Healthcare, On the Move]
- Monday, April 8, 7:25 AM Amarin (AMRN) gains 1.5% premarket after announcing significants reductions in apolipoprotein C-III levels in Phase 3 testing of Vascepa. Apo C-III is thought in inhibit the clearance of triglycerides from the blood. (PR) 1 Comment [Healthcare]
- Tuesday, April 2, 11:14 AM MKM Partners' Jon LeCroy is reiterating his Buy rating and $12 price target on Amarin (AMRN +1.8%) following last week's solid Vascepa weekly prescription data. LeCroy notes that if the current growth continues, assuming a wholesale cost of $184 per prescription and a prescription under-reporting rate of 22%, that would imply Q1 Vascepa sales of approximately $2.2M and Q2 of around $11M. So, while the consensus estimates still appear to be slightly high, LeCroy thinks that with stocking, they still could be attainable. 1 Comment [Healthcare, On the Move]
- Monday, April 1, 12:47 PM Amarin (AMRN +1%) gets a boost from some positive commentary out of Leerink Swann today, saying that Vascepa's prescription data appears to be tracking well. The firm notes that the largest TRx advance since the drug's launch was recorded last week, and the number of new prescriptions and refills are growing. Looking forward, Leerink thinks the AMRN's ramped-up marketing efforts and moves to obtain Tier 2 reimbursement should further accelerate TRx growth. 1 Comment [Healthcare, On the Move]
-
- View all 0 replies
-
- View all 0 replies
-
moeschempf
$AMRN Matthew Herper predicts FDA will grant Vascepa ANCHOR indication: http://onforb.es/10U6K46 - View all 0 replies
-
moeschempf
$AMRN from StreetInsider.com "Amarin (AMRN) Up as Vascepa Shows Strong Rx Growth Last Week"http://bit.ly/19LBbNh - View all 1 replies
-
-
- View all 3 replies
-
Quoth the Raven: Nice. I sold most of my under a buck position at between $1.90 - $2.05. Will buy back in for the long-term on a dip.
-
jcllier3: Order in for some July $2 calls @ 15 cents. Worst case I lose $450, best case, it goes to $3 or $4 and I make $3-$4k
-
- View all 0 replies
-
moeschempf
$AMRN Weekly V Rx growth has been outstanding,which translates into stellar mthly&qrtly growth. http://bit.ly/1az7bl4 - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
moeschempf
$AMRN from StreetInsider.com "Amarin (AMRN) Up as Vascepa Shows Strong Rx Growth Last Week"http://bit.ly/19LBbNh - View all 1 replies
-
-
Quoth the Raven
Feuerstein SLAMS Amarin, says FDA has "zero data" that will allow them to approve ANCHOR indication. $AMRN http://bit.ly/19a134R - View all 4 replies
-
moeschempf: Jeez, I guess AF hasn't read the published ANCHOR study, where all endpts. were met.
-
moeschempf: From AMRN Investor FAQ Question #1: Are results from REDUCE-IT required for approval of the ANCHOR indication?http://bit.ly/11UZiqO
-
- View all 3 replies
-
Quoth the Raven: Nice. I sold most of my under a buck position at between $1.90 - $2.05. Will buy back in for the long-term on a dip.
-
jcllier3: Order in for some July $2 calls @ 15 cents. Worst case I lose $450, best case, it goes to $3 or $4 and I make $3-$4k
-
Quoth the Raven
Amarin scripts in, up 7.5% from last week. Not terrible, but certainly not great. Time marches on and will tell the $AMRN tale... - View all 1 replies
-
fire0nice228: new slampiece from AF coming down the wire As Soon As Published
-
- View all 4 replies
-
-
-
Quoth the Raven
$AMRN loses $60 million on $2 million in sales, denied NCE status, stock almost green, longs loving it. Welcome to bizzaro world. $AMRN - View all 2 replies
-
joe kelly: Fish oil and the vagina are the two most powerful and mysterious forces in the universe. -
-
Quoth the Raven
$AMRN scipt data comes in light this Sunday; cash still burning, scripts barely a 6% gain. http://seekingalpha.com/a/uhat - View all 3 replies
-
-
Jareleft: Good medicine always sell well, &AMRN will be appreciated as it deserves, time will tell. Luck in your investments
-
Quoth the Raven
Amarin $AMRN burns $58 million in Q1. Holy hell. Potential to be out of cash before 2013 if things don't pick up big-time for Vascepa. - View all 2 replies
-
fire0nice228: you should delete this $AMRN comment too. You deleted a bad call on AMRN from Friday, don't forget about this one!
-
-
- View all 1 replies
-
fire0nice228: Why delete your ST from Friday about $AMRN popping green and ending red everyday? Because it was totally wrong and you got called on it?
-
Quoth the Raven
All eyes on Amarin after hours...what will the next chapter in the Amarin story be? $AMRN $SPY - View all 1 replies
-
-
- View all 1 replies
-
-
Brian L. Wilson
$AMRN followers - vascepa picked up growth again, and should support pps. More info here http://bit.ly/16brmYv - View all 2 replies
-
William LeGro: Be still my heart! Almost up to $7! Shhh! Don't tell the shorts!
-
William LeGro: Whoa! Possible stock offering? HZNP already pulled that on its investors. Don't want to see AMRN do it too, I can take only so much trauma.
-
- View all 3 replies
-
Quoth the Raven: Hey, don't get mad at me, I'M not the one that downgraded it! Cheers! ~QTR
-
JMattius: And look at it tank. Think they need more downgrades......
-
- View all 8 replies
-
rapsfan: @hatvani I bought at $7, should have sold at $14; hate that I got greedy
-
hatvani: My initial batch was at 9. Added more at 11.5 after the approval hoping for a rebound.
-
Quoth the Raven
Reality is starting to sink in for Amarin. Execute Vascepa launch correctly, or the company is heading for dilution. RT $6.39 $AMRN - View all 2 replies
-
Chris DeMuth Jr.: Snake oil salesmen. Wait, no, that's fish oil salesmen. -
